- The approval is based on two P-III studies assessing Orilissa 150 mg qd and 200 mg bid vs PBO enrolling 1,700 women with moderate to severe endometriosis pain
- P-III studies Results: showed reduction in daily menstrual pain and non-menstrual pelvic pain @6mos.; reduction in numeric rating scale (NRS) scores @3mos.; reduction in pain during sexual intercourse @3mos.
- Orilissa recommend doses 150mg qd and 200mg bid for up to 12mos is expected to be available in Canada from Nov’18
Click here to read full press release/ article | Ref: PRNewswire | Image: Barron